Focus On HR+ Cancers
Hormone receptor positive (HR+) cancers, including, prostate, breast, and ovarian result in >100,000 deaths per year in the United States. Decades old antihormonals and chemotherapies are still the most used therapies to treat these cancers.
Apristor® For PR+ Cancers
Our most advanced clinical-stage program, Apristor, is being investigated in breast and ovarian cancers. Because Apristor is the first pure progesterone receptor (PR) antagonist, the drug has the potential to improve overall survival by providing more complete hormonal blockade than dual PR agonist/antagonists.